Structure Therapeutics Inc
GPCR
查看详细走势图
64.940USD
+2.490+3.99%
收盘 12/19, 16:00（美东）报价延迟15分钟
3.94B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.99%
5天
-3.16%
1月
+89.22%
6月
+198.85%
今年开始到现在
+139.45%
1年
+132.76%
查看详细走势图
TradingKey Structure Therapeutics Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Structure Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
14
位分析师
买入
评级
77.077
目标均价
+10.14%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Structure Therapeutics Inc亮点
亮点风险
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-27.45，处于3年历史低位
机构减仓
最新机构持股57.81M股，环比减少19.53%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值111.90K
Structure Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Structure Therapeutics Inc简介
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
公司代码GPCR
公司Structure Therapeutics Inc
CEOStevens (Raymond)
网址https://structuretx.com/
常见问题
Structure Therapeutics Inc(GPCR)的当前股价是多少？
Structure Therapeutics Inc(GPCR)的当前股价是 64.940。
Structure Therapeutics Inc的股票代码是什么？
Structure Therapeutics Inc的股票代码是GPCR。
Structure Therapeutics Inc股票的52周最高点是多少？
Structure Therapeutics Inc股票的52周最高点是94.900。
Structure Therapeutics Inc股票的52周最低点是多少？
Structure Therapeutics Inc股票的52周最低点是13.220。
Structure Therapeutics Inc的市值是多少？
Structure Therapeutics Inc的市值是3.94B。
Structure Therapeutics Inc的净利润是多少？
Structure Therapeutics Inc的净利润为-122.53M。
现在Structure Therapeutics Inc(GPCR)的股票是买入、持有还是卖出？
根据分析师评级，Structure Therapeutics Inc(GPCR)的总体评级为买入，目标价格为77.077。
Structure Therapeutics Inc(GPCR)股票的每股收益（EPS TTM）是多少
Structure Therapeutics Inc(GPCR)股票的每股收益（EPS TTM）是-3.657。
相关品种
